Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany.
STAR Protoc. 2022 Dec 16;3(4):101708. doi: 10.1016/j.xpro.2022.101708. Epub 2022 Sep 20.
A major impediment to effective cellular therapies in solid tumors is the limited access of therapeutic cells to the tumor site. One strategy to overcome this challenge is to endow T cells with chemotactic properties required to access tumor tissue. Here, we present a chimeric antigen receptor (CAR)-modified T cell strategy centered around enhanced T cell trafficking. We outline isolation, activation, and transduction of human T cells, as well as techniques for assessing migratory and cytotoxic capacity of CAR-T cells. For complete details on the use and execution of this protocol, please refer to Lesch et al. (2021).
实体瘤中细胞疗法效果不佳的一个主要障碍是治疗细胞进入肿瘤部位的受限。克服这一挑战的一种策略是赋予 T 细胞能够进入肿瘤组织的趋化特性。在这里，我们提出了一种以增强 T 细胞迁移为中心的嵌合抗原受体 (CAR) 修饰 T 细胞策略。我们概述了人 T 细胞的分离、激活和转导，以及评估 CAR-T 细胞迁移和细胞毒性能力的技术。有关此方案使用和执行的完整详细信息，请参见 Lesch 等人。（2021 年）。
